For high-risk individuals with BRCA1 or BRCA2 mutations considering combined OCPs, genetics consultation should be considered to judge the competing impacts of increased breast cancer risk against individual needs and potential protective effects against ovarian cancer [175]. This evidence concerns the gene BRCA1 and breast carcinoma.